ACTU - ACTUATE THERAPEUTICS, INC.

QQQ $ 613.25 $ -11.61 (-1.86 %)

DIA $ 470.08 $ -3.83 (-0.81 %)

SPY $ 671.96 $ -7.27 (-1.07 %)

TLT $ 89.70 $ 0.80 (0.9 %)

GLD $ 366.78 $ -0.44 (-0.12 %)

Previous Close

$ 6.23

Open

$ 6.46

Bid

$ 6.17 x 50

Ask

$ 6.69 x 500

Day's Range

$ 6.23 - $ 6.42

52 Week Range

$ 5.47 - $ 11.99

Volume

18,650

Average Volume

Market Cap

129.24M

Beta (5Y Monthly)

$ 1.25

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-14-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	03-13-2025	12-31-2024	10-K
4	11-13-2024	09-30-2024	10-Q
5	09-24-2024	06-30-2024	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Actu...
09/23/2025 10:39:57

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintain...

Actuate Therapeutics Advances Elraglusib A...
09/22/2025 12:47:03

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current ...

12 Health Care Stocks Moving In Wednesday'...
09/10/2025 17:07:06

Actuate Therapeutics Prices $15M Public Of...
09/10/2025 12:39:17

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical compa...

12 Health Care Stocks Moving In Wednesday'...
09/10/2025 12:11:03

12 Health Care Stocks Moving In Tuesday's ...
09/09/2025 21:06:08

Actuate Therapeutics Announces Underwritte...
09/09/2025 20:19:35

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical compa...

Actuate Therapeutics Files For Mixed Shelf...
09/02/2025 20:38:52

-SEC Filing

this-actuate-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-tuesday

This Actuate Therapeutics Analyst Begins C...
08/26/2025 11:49:01

B. Riley Securities Initiates Coverage On ...
08/26/2025 10:22:43

B. Riley Securities analyst Mayank Mamtani initiates coverage on Actuate Therapeutics (NASDAQ:ACTU) with a Buy rating and an...

HC Wainwright & Co. Reiterates Buy on Actu...
08/18/2025 10:31:41

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintain...

Actuate Therapeutics Q2 EPS $(0.30) Beats ...
08/14/2025 21:49:57

Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of ...

Actuate Therapeutics Initiates Phase 1b Tr...
08/06/2025 12:47:03

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline TherapyCHICAGO and FORT ...

Actuate Therapeutics Initiates Planning Of...
07/17/2025 12:47:51

Actuate Therapeutics Announces End Of Phas...
07/17/2025 12:46:59

12 Health Care Stocks Moving In Friday's P...
06/27/2025 12:07:16

12 Health Care Stocks Moving In Thursday's...
06/26/2025 21:05:50

On June 25, 2025, Actuate Therapeutics Ent...
06/26/2025 12:15:25

On June 25, 2025, Actuate Therapeutics, Inc. (the "Company") entered into a securities purchase agreement (the "Se...

Actuate Therapeutics Highlights Results Fr...
06/24/2025 13:22:04

- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in ris...

Actuate Therapeutics Highlights Biomarker,...
06/20/2025 12:48:38

The poster described an analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors (CCSGs) from plasma sa...